Brokerages Expect Bristol-Myers Squibb Co (BMY) Will Post Quarterly Sales of $5.29 Billion

Equities analysts predict that Bristol-Myers Squibb Co (NYSE:BMY) will post sales of $5.29 billion for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Bristol-Myers Squibb’s earnings. The highest sales estimate is $5.43 billion and the lowest is $5.20 billion. Bristol-Myers Squibb posted sales of $5.24 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1%. The firm is expected to issue its next earnings report on Thursday, January 25th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full-year sales of $5.29 billion for the current financial year, with estimates ranging from $20.44 billion to $20.77 billion. For the next year, analysts forecast that the firm will report sales of $21.16 billion per share, with estimates ranging from $20.82 billion to $21.51 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter last year, the firm earned $0.77 earnings per share. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year.

A number of analysts have commented on BMY shares. Goldman Sachs Group reiterated a “buy” rating and set a $65.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 target price on the stock. in a research report on Thursday, September 7th. Credit Suisse Group reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research report on Friday, September 8th. Jefferies Group boosted their target price on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Finally, Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price on the stock. in a research report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $64.42.

Bristol-Myers Squibb (NYSE:BMY) traded up $0.08 during trading on Friday, hitting $61.83. The company had a trading volume of 1,232,717 shares, compared to its average volume of 6,769,900. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb has a 12-month low of $46.01 and a 12-month high of $66.10. The stock has a market capitalization of $101,700.00, a P/E ratio of 24.34, a PEG ratio of 2.21 and a beta of 1.18.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.59%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is 61.42%.

In related news, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. acquired a new position in Bristol-Myers Squibb in the first quarter valued at $8,157,000. Segantii Capital Management Ltd acquired a new position in Bristol-Myers Squibb in the first quarter valued at $544,000. Columbia Asset Management increased its stake in Bristol-Myers Squibb by 4.1% in the first quarter. Columbia Asset Management now owns 16,574 shares of the biopharmaceutical company’s stock valued at $901,000 after purchasing an additional 650 shares during the last quarter. Legal & General Group Plc increased its stake in Bristol-Myers Squibb by 4.3% in the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock valued at $446,664,000 after purchasing an additional 335,795 shares during the last quarter. Finally, State Street Corp increased its stake in Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after purchasing an additional 1,223,457 shares during the last quarter. 69.66% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/brokerages-expect-bristol-myers-squibb-co-bmy-will-post-quarterly-sales-of-5-29-billion.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply